Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLR NASDAQ:LIXT NASDAQ:ONCY NASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.43-7.7%$1.44$0.77▼$2.35$24.66M0.52228,384 shs336,492 shsLIXTLixte Biotechnology$6.19-14.6%$4.74$0.64▼$7.51$108.89M1.27211,115 shs871,824 shsONCYOncolytics Biotech$0.80-2.1%$0.93$0.54▼$1.51$97.87M1.071.56 million shs649,499 shsTHARTharimmune$3.02+2.4%$3.18$0.95▼$9.08$178.84M1.431.48 million shs1.17 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics+4.03%-8.82%+1.97%+23.02%+75.52%LIXTLixte Biotechnology+5.22%+3.57%+43.00%+133.12%+489.43%ONCYOncolytics Biotech+2.49%-5.42%-9.22%-16.67%+43.21%THARTharimmune+10.07%+24.47%-7.52%-29.68%+87.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.43-7.7%$1.44$0.77▼$2.35$24.66M0.52228,384 shs336,492 shsLIXTLixte Biotechnology$6.19-14.6%$4.74$0.64▼$7.51$108.89M1.27211,115 shs871,824 shsONCYOncolytics Biotech$0.80-2.1%$0.93$0.54▼$1.51$97.87M1.071.56 million shs649,499 shsTHARTharimmune$3.02+2.4%$3.18$0.95▼$9.08$178.84M1.431.48 million shs1.17 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics+4.03%-8.82%+1.97%+23.02%+75.52%LIXTLixte Biotechnology+5.22%+3.57%+43.00%+133.12%+489.43%ONCYOncolytics Biotech+2.49%-5.42%-9.22%-16.67%+43.21%THARTharimmune+10.07%+24.47%-7.52%-29.68%+87.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 2.00Hold$10.25616.78% UpsideLIXTLixte Biotechnology 1.00SellN/AN/AONCYOncolytics Biotech 2.75Moderate Buy$8.50958.53% UpsideTHARTharimmune 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ALLR, ONCY, THAR, and LIXT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026ALLRAllarity Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.75 ➝ $10.255/29/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026ONCYOncolytics Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/12/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026ALLRAllarity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026ALLRAllarity Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.50 ➝ $9.753/27/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity Therapeutics$320K71.10N/AN/A$0.61 per share2.34LIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/ATHARTharimmuneN/AN/AN/AN/A$0.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$11.23M-$0.72N/AN/AN/AN/A-109.94%-47.27%8/21/2026 (Estimated)LIXTLixte Biotechnology-$6.01M-$1.13N/AN/AN/AN/A-134.91%-95.61%N/AONCYOncolytics Biotech-$28.76M-$0.31N/AN/AN/AN/A-2,185.97%-321.54%7/31/2026 (Estimated)THARTharimmune-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%N/ALatest ALLR, ONCY, THAR, and LIXT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ALLRAllarity Therapeutics-$0.22-$0.17+$0.05-$0.17$0.03 million$0.03 million5/14/2026Q1 2026LIXTLixte BiotechnologyN/A-$0.18N/A-$0.18N/AN/A5/14/2026Q1 2026ONCYOncolytics Biotech-$0.05-$0.08-$0.03-$0.08N/AN/A3/31/2026Q4 2025ONCYOncolytics Biotech-$0.06-$0.08-$0.02-$0.08N/AN/A3/30/2026Q4 2025ALLRAllarity Therapeutics-$0.22-$0.21+$0.01-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A1.231.23LIXTLixte BiotechnologyN/A2.782.78ONCYOncolytics BiotechN/A1.381.38THARTharimmuneN/A4.984.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%LIXTLixte Biotechnology5.10%ONCYOncolytics Biotech6.82%THARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%LIXTLixte Biotechnology9.50%ONCYOncolytics Biotech0.10%THARTharimmune6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.91 million15.90 millionNot OptionableLIXTLixte Biotechnology415.02 million13.59 millionNot OptionableONCYOncolytics Biotech30119.35 million119.24 millionNot OptionableTHARTharimmune237.73 million35.20 millionNot OptionableALLR, ONCY, THAR, and LIXT HeadlinesRecent News About These CompaniesTharimmune (NASDAQ:THAR) Trading Up 15.2% - Still a Buy?June 10 at 2:55 AM | americanbankingnews.comTharimmune Inc.May 13, 2026 | wsj.comTharimmune Rebrands as Canton Strategic Holdings, Updates TickerFebruary 18, 2026 | tipranks.comIs Canton’s price set to explode amid Tharimmune’s rebrand?February 17, 2026 | invezz.comITharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury StrategyFebruary 17, 2026 | prnewswire.comCatherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio ImpactFebruary 11, 2026 | finance.yahoo.comTharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating OfficerFebruary 6, 2026 | prnewswire.comTharimmune Elects Jill Sommers and William Wiley to Board of DirectorsFebruary 2, 2026 | prnewswire.comTharimmune Approved as Super Validator on Canton NetworkJanuary 27, 2026 | theglobeandmail.comTharimmune Announces Expanded Role as Super Validator on Canton NetworkJanuary 26, 2026 | prnewswire.comTharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On TokenizationJanuary 23, 2026 | seekingalpha.comTharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct OfferingJanuary 22, 2026 | prnewswire.comTharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered OfferingJanuary 20, 2026 | prnewswire.comTharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton NetworkDecember 18, 2025 | prnewswire.comTharimmune appoints Jacob Asbury as CFODecember 12, 2025 | msn.comTharimmune Appoints Jacob Asbury as New CFODecember 12, 2025 | tipranks.comTharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury StrategyDecember 12, 2025 | businesswire.comTharimmune files to sell 176.93M shares of common stock for holdersDecember 5, 2025 | msn.comCrypto Company Creates Bizarre DrugNovember 22, 2025 | msn.comTharimmune (NASDAQ:THAR) Shares Up 8.9% – What’s Next?November 22, 2025 | defenseworld.netDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALLR, ONCY, THAR, and LIXT Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.43 -0.12 (-7.74%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.02 (+1.05%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Lixte Biotechnology NASDAQ:LIXT$6.19 -1.06 (-14.62%) Closing price 04:00 PM EasternExtended Trading$6.42 +0.23 (+3.80%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Oncolytics Biotech NASDAQ:ONCY$0.80 -0.02 (-2.07%) Closing price 04:00 PM EasternExtended Trading$0.82 +0.01 (+1.49%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Tharimmune NASDAQ:THAR$3.02 +0.07 (+2.37%) As of 06/11/2026Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
